<--- Back to Details
First PageDocument Content
Food and Drug Administration / Pharmaceuticals policy / Drug discovery / Orphan drug / Pharmaceutical industry / FDA Fast Track Development Program / Criticism of the Food and Drug Administration / Orphan Drug Act / Pharmaceutical sciences / Pharmacology / Clinical research
Date: 2013-12-24 07:18:09
Food and Drug Administration
Pharmaceuticals policy
Drug discovery
Orphan drug
Pharmaceutical industry
FDA Fast Track Development Program
Criticism of the Food and Drug Administration
Orphan Drug Act
Pharmaceutical sciences
Pharmacology
Clinical research

Add to Reading List

Source URL: pluristem.com

Download Document from Source Website

File Size: 189,15 KB

Share Document on Facebook

Similar Documents

The NIH Undiagnosed Diseases Program J A M E S P A N • 10 J U N E 2014 Stanford University School of Medicine In the United States, a rare disease defined by the 1983 Orphan Drug Act, is a disease that affects fewer

DocID: 1uQtE - View Document

Development of new in silico methods to identify ligands for orphan GPCRs. Nathanael Weill and Didier Rognan. Bioinformatics of the Drug, UMR7175, Université Louis Pasteur Strasbourg, 74, route du Rhin, B.P.24 FI

DocID: 1uh67 - View Document

Health / Medicine / Epidemiology / Medical terminology / Rare diseases / Medical diagnosis / Global Genes / European Organisation for Rare Diseases / Orphan drug / Disease / Rare Disease Day / Draft:Rare Cancers

Edelman-DiagnosisDoesntHaveToBeRareLogoV3

DocID: 1rkUk - View Document

Medical research / Health / Drug discovery / Clinical research / Epidemiology / Pharmaceuticals policy / Design of experiments / Orphan drug / Clinical trial / Rare disease / European Medicines Agency / Draft:Rare Cancers

Centre européen de biologie et de génomique structurales (CEBGS), unité 964 "Institut de génétique et de biologie moléculaire et cellulaire (IGBMC), Illkirch.

DocID: 1r6Sz - View Document

Pharmaceuticals policy / Health / Pharmaceutical industry / Pharmacology / European Medicines Agency / European Union / Marketing authorization / European Directorate for the Quality of Medicines / EudraLex / European Pharmacopoeia / Orphan drug / Supplementary protection certificate

emea_strap_url_cmyk_rev_en_std_cent.eps MASTER

DocID: 1qVx6 - View Document